Ruxolitinib, a JAK1/JAK2 Selective Inhibitor Is Highly Efficacious in Corticosteroid Untreated and Refractory MHC-Mismatched Mouse Model of Acute GvHD von Juvekar, Ashish, Ruggeri, Bruce, Condon, Sindy, Borkowski, Andrew, Huber, Reid, Smith, Paul

Volltext

Itacitinib, a JAK1 Selective Inhibitor Preserves Graft-Versus-Leukemia (GVL), Enhances Survival and Is Highly Efficacious in a MHC-Mismatched Mouse Model of Acute GvHD von Juvekar, Ashish, Ruggeri, Bruce, Condon, Sindy, Borkowski, Andrew, Huber, Reid, Smith, Paul

Volltext

Abstract 1876: INCB052793, a JAK1 selective inhibitor, is highly efficacious in PDX and xenograft models of acute myeloid leukemia (AML) expressing elevated endogenous pSTAT3/pSTAT... von Juvekar, Ashish, Condon, Sindy, Wen, Xiaoming, Ruggeri, Bruce, Scherle, Peggy, Huber, Reid, Li, Yunlong, Yao, Wenqing, Mei, Song, Bhasin, Deepak, Mancini, Maria

Volltext

Abstract 2100: Selective inhibition of FGFR4 by INCB062079 is efficacious in models of FGF19- and FGFR4-dependent cancers von Liu, Phillip C.C., Lu, Liang, Bowman, Kevin, Stubbs, Matthew C., Wu, Liangxing, DiMatteo, Darlise, Condon, Sindy, Klabe, Ronald, Qian, Ding-Quan, Wen, Xiaoming, Collier, Paul, Gallagher, Karen, Hansbury, Michael, He, Xin, Ruggeri, Bruce, Yang, Yan-ou, Covington, Maryanne, Burn, Timothy C., Diamond-Fosbenner, Sharon, Wynn, Richard, Huber, Reid, Yao, Wenqing, Yeleswaram, Swamy, Scherle, Peggy, Hollis, Gregory

Volltext

Abstract 1234: The novel FGFR4-selective inhibitor INCB062079 is efficacious in models of hepatocellular carcinoma harboring FGF19 amplification von Ruggeri, Bruce, Stubbs, Matthew, Yang, Yan-ou, Juvekar, Ashish, Lu, Liang, Condon, Sindy, DiMatteo, Darlise, Wen, Xiaoming, Collier, Paul, Burn, Timothy, Wu, Liangxing, Wilson, Daniel, Yeleswaram, Swamy, Roberts, Alan, Yao, Wenqing, Hollis, Gregory, Huber, Reid, Scherle, Peggy, Liu, Phillip CC

Volltext